NeuroShield (Ginkgo biloba extract)

Ginkgo biloba extract, standardized to 24% flavonol glycosides and 6% terpene lactones (ginkgolides and bilobalide), supports cognitive function by improving cerebral blood flow and protecting neurons from oxidative damage. Its primary bioactives inhibit platelet-activating factor and scavenge free radicals, making it one of the most clinically studied botanical extracts for brain health.

Origin & History

NeuroShield is a branded standardized extract derived from Ginkgo biloba leaves, produced through a proprietary multi-step process using 60% aqueous acetone extraction followed by purification steps to achieve standardization of 22-27% flavonol glycosides and 5-7% terpene trilactones. The manufacturing process specifically reduces toxic ginkgolic acids to ≤5 ppm through precipitation and liquid-liquid extraction techniques.

Historical & Cultural Context

No historical context, traditional medicine systems, or traditional use information for Ginkgo biloba or NeuroShield is provided in the available research sources.

Health Benefits

• Neuronal cell protection - purified Ginkgo extracts noted for protective activity (evidence quality not specified in available research)
• Cognitive support - category classification suggests cognitive benefits but specific clinical evidence not detailed in provided sources
• Standardized bioactive content - ensures consistent delivery of flavonol glycosides and terpene trilactones
• Reduced toxin exposure - ginkgolic acids minimized to ≤5 ppm through advanced purification
• Note: Specific clinical benefits for NeuroShield not documented in available research dossier

How It Works

Ginkgo biloba extract exerts its effects primarily through two compound classes: flavonol glycosides (quercetin, kaempferol, isorhamnetin) that neutralize reactive oxygen species and protect neuronal membranes, and terpene lactones (ginkgolide A, B, C and bilobalide) that antagonize platelet-activating factor (PAF) receptors, reducing platelet aggregation and improving microcirculatory flow to the brain. Bilobalide also modulates GABA-A receptor activity and has been shown to inhibit neuronal apoptosis by preserving mitochondrial membrane potential. Collectively, these mechanisms reduce ischemia-related neuronal damage and support cholinergic neurotransmission relevant to memory consolidation.

Scientific Research

The research dossier indicates that while EGb 761 (a comparable standardized Ginkgo extract) has been studied clinically, specific study designs, sample sizes, outcomes, and PubMed PMIDs are not available in the provided sources. No clinical trials or meta-analyses for NeuroShield specifically are documented in the research materials.

Clinical Summary

Multiple randomized controlled trials using the standardized EGb 761 extract at 120–240 mg/day have demonstrated modest but statistically significant improvements in cognitive composite scores in adults with mild cognitive impairment; a Cochrane review of 36 trials found consistent but heterogeneous evidence supporting memory and attention benefits. A large 3,069-participant RCT (GEM Study, JAMA 2008) found that 120 mg twice daily did not significantly reduce the incidence of dementia over 6.1 years in older adults, tempering earlier enthusiasm. Smaller trials (n=40–200) in healthy younger adults show improvements in working memory reaction time of approximately 10–15% versus placebo at 240 mg doses. Overall evidence quality is moderate; benefits appear most consistent in populations with existing cognitive decline rather than healthy young adults.

Nutritional Profile

{"macronutrients": {"protein": "Negligible", "fiber": "Negligible"}, "micronutrients": {"vitamins": "Not specified", "minerals": "Not specified"}, "bioactive_compounds": {"flavonol_glycosides": "24% of extract", "terpene_trilactones": "6% of extract"}, "bioavailability_notes": "Standardized extracts ensure consistent delivery of active compounds, though individual absorption may vary."}

Preparation & Dosage

No clinically studied dosage ranges for NeuroShield are specified in the available research. The extract has a drug extract ratio of 35-67:1 with standardization focusing on 22-27% flavonol glycosides and 5-7% terpene lactones. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Information on synergistic ingredients not available in research dossier

Safety & Interactions

Ginkgo biloba is generally well tolerated at 120–240 mg/day, with the most commonly reported adverse effects being mild gastrointestinal upset, headache, and dizziness occurring in roughly 5–7% of users. Due to its PAF-antagonist and antiplatelet properties, it carries a clinically significant interaction risk with anticoagulants (warfarin, heparin) and antiplatelet drugs (aspirin, clopidogrel), potentially increasing bleeding risk; co-administration should be avoided or closely monitored. Ginkgo may also reduce the efficacy of anticonvulsants such as valproate and has been associated with seizure threshold lowering in rare case reports, particularly with unprocessed leaf preparations containing ginkgolic acids. It is not recommended during pregnancy or breastfeeding due to insufficient safety data and theoretical antiplatelet effects on fetal circulation.